PubMed

Clinical trial design in FDA submissions for neuromodulation devices, 1960-2023: a systematic review and meta-analysis.

PMID: 40542709 · 2025-07-06

B, a, s, s, e, l, , A, l, m, a, r, i, e, ;, , K, e, v, i, n, , P, a, c, h, e, c, o, -, B, a, r, r, i, o, s, ;, , A, n, n, a, , C, a, r, o, l, y, n, a, , G, i, a, n, l, o, r, e, n, c, o, ;, , Y, a, s, m, i, n, , E, l, t, a, w, i, l, ;, , A, l, m, a, , S, a, n, c, h, e, z, ;, , F, e, l, i, p, e, , F, r, e, g, n, i

학술지Expert review of medical devices

연도2025-07-06

PMID40542709

초록

Integration of clinical trials into FDA approval processes is essential for ensuring the safety and efficacy of neuromodulation devices. From 1960 to 2023, 125 FDA-approved neuromodulation records corresponding to 109 publications (64 randomized, 45 nonrandomized trials) were identified. Regulatory records and published trial characteristics were reviewed. Safety outcomes were reported in 95.4% of randomized and 82.2% of nonrandomized trials, with serious adverse events in ~ 75% of the studies.

공식 출처

PubMed에서 보기 →

데이터는 PubMed / NCBI에서 제공됩니다. 전문과 최신 정보는 반드시 공식 기록을 확인하세요.